secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001437749-26-006821
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azenta acquires UK Biocentre for GBP 20.5M to expand European biorepository footprint
--------------------------------------------------------------------------------

- Total consideration of GBP 20.5M net of cash, including up to GBP 1.8M contingent milestone payments.
- UK Biocentre generated approx GBP 15.3M revenue in twelve months ended Sep 30, 2025.
- Deal expected to be dilutive to FY2026 Adj EBITDA margin by ~35bps, accretive to FY2027/2028 revenue growth and margin.
- UK Biocentre will operate as European hub, adding automated high-throughput capacity and BioArc™ Ultra deployment.
- Conference call to discuss transaction scheduled for March 10, 2026 at 10:00 am ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000143774926006821/0001437749-26-006821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000143774926006821/azta20260303_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-006821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer